Professional development Vacancies

Regarding amendments to the instructions for medical use of medicinal products containing Biotin

28.02.2019 Updated 26.11.2020 2536 views

Dear applicants!

The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC EMA), having reviewed all available evidence from the literature and EudraVigilance, considers that there is sufficient evidence to confirm a potential impact on clinical laboratory test results of medicinal products for oral use containing ≥150 µg of biotin per dose and medicinal products for parenteral use containing ≥60 µg of biotin per dose unit. The PRAC agreed that registration certificate holders of medicinal products containing Biotin for oral and parenteral use must, within 3 months (from the date – see the reference), amend the section “Special warnings and precautions for use” of the instructions for medical use by adding information on the impact on the results of clinical laboratory tests of medicinal products containing biotin.

List of medicinal products containing Biotin, and authorized for medical use in Ukraine (according to the State Register of Medicinal Products as of 12.02.2019.

Link:

https://www.ema.europa.eu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019_en.pdf

https://www.ema.europa.eu/documents/prac-recommendation/prac-recommendations-signals-adopted-14-17-january-2019-prac-meeting_en.pdf